HAG
TEVA icon

HighPoint Advisor Group’s Teva Pharmaceuticals TEVA Stock Holding History

HighPoint Advisor Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,132
Closed -$426K – 706
2026
Q1 		$426K Sell
14,132
-16,308
-54% -$525K 0.02% 454
2025
Q4 		$950K Buy
+30,440
New +$750K 0.02% 481
2021
Q3 		$98K Buy
+10,056
New +$94.2K 0.01% 535
2019
Q3 		– Sell
-12,356
Closed -$95K – 517
2019
Q2 		$95K Sell
12,356
-564
-4% -$6.8K 0.02% 471
2019
Q1 		$188K Buy
12,920
+1,035
+9% +$18.3K 0.05% 314
2018
Q4 		$214K Buy
11,885
+1,153
+11% +$23.6K 0.06% 280
2018
Q3 		$228K Buy
+10,732
New +$249K 0.06% 276
2017
Q1 		– Sell
-6,250
Closed -$219K – 301
2016
Q4 		$219K Buy
6,250
+1,010
+19% +$40.3K 0.07% 254
2016
Q3 		$204K Buy
5,240
+916
+21% +$47.8K 0.07% 256
2016
Q2 		$231K Buy
+4,324
New +$230K 0.08% 238

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

HighPoint Advisor Group's TEVA Position: Q2 2026 in Review

HighPoint Advisor Group sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 14,132 shares — an estimated $426K sold.

HighPoint Advisor Group first reported a position in TEVA in Q2 2016 and held it in 10 quarters. The position peaked at $950K in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • HighPoint Advisor Group reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • HighPoint Advisor Group sold 14,132 Teva Pharmaceuticals shares in Q2 2026, an estimated $426K.
  • HighPoint Advisor Group first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 10 quarters.
  • HighPoint Advisor Group's Teva Pharmaceuticals position peaked at $950K in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on HighPoint Advisor Group's 13F filing for Q2 2026, filed 5 Aug 2026.